pyrazines has been researched along with gemfibrozil in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cramb, R; Head, A; Jakeman, PM; Kendall, MJ; Maxwell, S | 1 |
| Luley, C; Orth, M | 1 |
| Bergemann, R; Brandt, A; Siegrist, W | 1 |
| Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD | 1 |
| B, S; Dubala, A; K P, A; K, E; Kucherlapati, VS; M, D; Meda, VS; P R, AV | 1 |
| Boehler, M; Bruderer, S; Dingemanse, J; Halabi, A; Petersen-Sylla, M; Remeňová, T | 1 |
4 trial(s) available for pyrazines and gemfibrozil
| Article | Year |
|---|---|
The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Blood Pressure; Energy Metabolism; Exercise; Exercise Test; Exercise Tolerance; Fatty Acids, Nonesterified; Gemfibrozil; Heart Rate; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lovastatin; Male; Oxidation-Reduction; Oxygen Consumption; Pyrazines; Random Allocation; Simvastatin; Single-Blind Method | 1993 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides | 1999 |
Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.
Topics: Adult; Biological Availability; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Gemfibrozil; Half-Life; Humans; Hypolipidemic Agents; India; Male; Metabolic Clearance Rate; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2012 |
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Topics: Acetamides; Acetates; Activation, Metabolic; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Gemfibrozil; Germany; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prodrugs; Pyrazines; Rifampin; Risk Assessment; Young Adult | 2017 |
2 other study(ies) available for pyrazines and gemfibrozil
| Article | Year |
|---|---|
Diagnostic pitfalls during therapy for extreme hypertriglyceridaemia.
Topics: Adult; Cholesterol, LDL; Combined Modality Therapy; Docosahexaenoic Acids; Eicosapentaenoic Acid; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Pyrazines; Triglycerides | 1997 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome | 1993 |